Today: 10 June 2026
Browse Category

NASDAQ:BIIB 25 August 2025 - 21 May 2026

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, ending APLS trading on Nasdaq as of May 15. Former Apellis shareholders receive $41 per share in cash and a contingent value right tied to future Syfovre sales. Biogen shares rose 0.6% early Thursday. The CVR pays only if Syfovre meets specific sales milestones; there is no guarantee of payout.
21 May 2026
···
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
20 May 2026
····
Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
15 May 2026
···
Why Nvidia, Cisco, Cerebras, Boeing and Biogen Are the US Stocks to Watch Today

Why Nvidia, Cisco, Cerebras, Boeing and Biogen Are the US Stocks to Watch Today

Cisco will cut nearly 4,000 jobs and raised its annual revenue forecast after AI infrastructure orders hit $5.3 billion. Nvidia shares remain sensitive to U.S.-China chip policy after U.S. officials cleared Chinese firms to buy H200 processors, though no shipments have occurred. Cerebras debuted with a $5.55 billion IPO, opening at $350 per share. Boeing shares fell after China pledged to buy 200 jets, fewer than expected.
15 May 2026
······
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen shares traded near $175 on Dec. 22 as the company announced JAMA Neurology published final long-term results from its Phase 3 VALOR study of QALSODY for SOD1-ALS. The stock was removed from the Nasdaq-100 index today, following a surge in volume last Friday. Analyst ratings remain mixed, with price targets ranging from the low-$140s to above $200.
22 December 2025
·
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen shares closed at $174.80 on Dec. 19, up 2.88% with trading volume spiking to 15 million shares, well above the 50-day average. The stock remains about 5% below its 52-week high of $185.17. Recent filings show new institutional positions from Wedge Capital Management and Fluent Financial. Leqembi was added to China’s Commercial Insurance Innovative Drug List, effective Jan. 1, 2026.
21 December 2025
··
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen shares closed up 2.88% at $174.80 Friday, with trading volume surging to about 15 million shares, far above the 50-day average. The move followed bullish analyst commentary from RBC Capital, which reiterated an “Outperform” rating and a $210 price target. After-hours, BIIB edged higher to $176.23. Renewed focus on Alzheimer’s treatments and pipeline prospects drove activity.
20 December 2025
·
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • Senior PLC Shareholding Update: Societe Generale Increases Stake
    June 10, 2026, 5:43 AM EDT. Senior PLC has received a notification from Societe Generale regarding a change in its major shareholdings. As of June 8, 2026, Societe Generale's voting rights in Senior PLC rose to 8.508%, up from 7.16%. This increase results from the acquisition of direct voting rights attached to shares and a small position through financial instruments, specifically a contract for difference (CFD). The total number of voting rights held reached 35,683,656. Societe Generale is based in London and does not control any other entities with interests in Senior PLC. The notification reflects a notable shift in shareholder composition ahead of potential corporate developments.

Latest articles

Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle Faces $600 Billion AI Bet as Traders Watch for Volatility

10 June 2026
Oracle shares slid nearly 3% to $205.81 ahead of Wednesday’s earnings, as investors await proof that its $553 billion AI cloud backlog can convert to revenue quickly enough to justify heavy data-center spending, with options pricing signaling an 11% stock swing after results.
DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

10 June 2026
DraftKings shares soared 11.34% to $27.59 after revealing a 24% month-over-month jump in annualized consumer volume to $1.3 billion and a 34% rise in total volume traded to $3.1 billion in its Predictions product for May, based on preliminary, unaudited data, outpacing a falling Nasdaq and spotlighting investor focus on the product’s revenue potential and DraftKings’ strategic push.
Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

10 June 2026
Micron shares fell 1.5% to $935.89 as the AI-chip rally cooled, despite bullish analyst calls and price targets up to $1,625; investors await the June 24 earnings report to see if tight memory chip supply and AI demand can sustain the stock’s trillion-dollar valuation amid broader market jitters and shifting sentiment.
Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

Ondas Dips Premarket After 2.7 Million-Share Filing

10 June 2026
SoFi Technologies traded near $16.47 in early premarket, little changed as investors weighed its AI and digital asset product push against a risk-off market mood, with no fresh earnings news and inflation data looming that could impact rates, loan demand, and fintech valuations.
Ondas Dips Premarket After 2.7 Million-Share Filing

SoFi Stock Holds Ahead of Pre-Market Test as Wall Street Grows Defensive

10 June 2026
Rolls-Royce shares rebounded 1.5% in London after Tuesday’s 2.68% drop, as investors weighed fresh airline criticism over engine delays against the company’s reaffirmed 2026 profit and cash flow guidance; CEO Tufan Erginbilgic said Rolls had a “strong start to the year,” but risks remain if airline pressure leads to higher costs or slower cash conversion.
Go toTop